Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Treatment of Insomnia in Patients With HIV Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00465972
First received: April 25, 2007
Last updated: July 26, 2013
Last verified: May 2013

April 25, 2007
July 26, 2013
March 2007
August 2010   (final data collection date for primary outcome measure)
Response: Change in Insomnia Severity Rating Scale at 3 Months. [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: No ]
Insomnia Severity Index; It is a measure of Insomnia Severity; A higher number indicates greater severity of insomnia. Range of possible score totals is 0-28.
Response: Effect upon an insomnia severity rating scale at 3 and 6 months.
Complete list of historical versions of study NCT00465972 on ClinicalTrials.gov Archive Site
Change in Piper Fatigue Scale at 3 Months [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: No ]
A 22 item scale measuring level of fatigue, with possible totals ranging from 22-220. A higher number indicates greater severity of fatigue.
Response: effect upon cytokine analysis, fatigue, immune measures, and adherence.
Not Provided
Not Provided
 
The Treatment of Insomnia in Patients With HIV Disease
A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Doxepin and Temazepam in HIV Seropositive Patients With Insomnia.

This study is designed to evaluate the efficacy of two commonly prescribed sleep aids for use in patients who are HIV positive and suffer from insomnia.

Insomnia is a disorder defined as persistent difficulty falling asleep, staying asleep or non-restorative sleep which is associated with diminished daytime function without any identifiable underlying cause. This condition is extremely common among HIV infected individuals and can lead to significant distress and reduction in the quality of life. The mechanisms for disrupted sleep in this population are diverse, including potential direct effects of the tat protein upon the sleep centers in the central nervous system. Insomnia has been documented to be one of the most common psychiatric disorders in HIV disease, but no trial has systematically examined the efficacy of available hypnotic agents, which are commonly used in this population.

Comparison(s): Two commonly prescribed hypnotic agents used for insomnia will be compared to placebo over a 6 month treatment study.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • HIV Infections
  • Insomnia
  • Drug: Doxepin
    Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
  • Drug: Temazepam
    Temazepam capsule 15 mg po nightly x duration of study
  • Drug: Placebo
    Placebo capsule nightly for duration of study
  • Placebo Comparator: Placebo
    Placebo
    Intervention: Drug: Placebo
  • Active Comparator: 2
    Doxepin
    Intervention: Drug: Doxepin
  • Active Comparator: 3
    Temazepam
    Intervention: Drug: Temazepam

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
44
August 2010
August 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Insomnia
  • HIV Seropositive
  • Stable HIV Disease

Exclusion Criteria:

  • Other psychiatric illnesses
  • Unstable HIV disease
Both
18 Years to 69 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00465972
8899
Yes
Duke University
Duke University
Not Provided
Principal Investigator: Andrew D Krystal, MD Duke University
Duke University
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP